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Abstract 
Thrombotic microangiopathies (TMAs) rep-
resent  a  heterogeneous  group  of  diseases
characterized by a microangiopathic hemolytic
anemia,  peripheral  thrombocytopenia,  and
organ failure of variable severity. TMAs encom-
pass  thrombotic  thrombocytopenic  purpura
(TTP), typically characterized by fever, central
nervous system manifestations and hemolytic
uremic syndrome (HUS), in which renal fail-
ure is the prominent abnormality. In patients
with cancer TMAs may be related to various
antineoplastic drugs or to the malignant dis-
ease itself. The reported series of patients with
TMAs directly related to cancer are usually het-
erogeneous,  retrospective,  and  encompass
patients with hematologic malignancies with
solid tumors or receiving chemotherapy, each
of which may have distinct presentations and
pathophysiological mechanisms. Patients with
disseminated  malignancy  who  present  with
microangiopathic  hemolytic  anemia  and
thrombocytopenia  may  be  misdiagnosed  as
thrombotic  thrombocytopenic  purpura  (TTP)
Only a few cases of TTP secondary to metasta-
tic adenocarcinoma are known in the litera-
ture. We present a case of a 34-year-old man
with  TTP  syndrome  secondary  to  metastatic
small-bowel  adenocarcinoma.  Patients  with
disseminated malignancy had a longer dura-
tion of symptoms, more frequent presence of
respiratory symptoms, higher lactate dehydro-
genase levels, and more often failed to respond
to  plasma  exchange  treatment.  A  search  for
systemic malignancy, including a bone marrow
biopsy, is appropriate when patients with TTP
have atypical clinical features or fail to respond
to plasma exchange. 
Introduction
The initial diagnosis of thrombotic thrombo-
cytopenic  purpura  (TTP)  may  be  uncertain
because  other  disorders  that  can  cause
microangiopathic hemolytic anemia and throm-
bocytopenia,  the  principal  diagnostic  criteria,
may  not  be  initially  apparent.1 Disseminated
malignancy  is  an  important  consideration  in
the differential diagnosis of TTP since cancer
has been well described for many years as a
cause  of  microangiopathic  hemolytic  anemia
and  thrombocytopenia.2-7 Although  in  most
patients  the  disseminated  malignancy  that
causes microangiopathic hemolytic anemia and
thrombocytopenia is easily recognized, in some
patients, the malignancy is not clinically appar-
ent, and therefore TTP is diagnosed and plasma
exchange treatment is begun. Failure to diag-
nose  disseminated  malignancy  exposes  the
patient to the major risks of plasma exchange
and causes delay of appropriate chemotherapy.8
However,  failure  to  urgently  initiate  plasma
exchange treatment in a patient with TTP may
result  in  death.  The  thrombotic  microan-
giopathies are a group of syndromes character-
ized  by  small-vessel  thrombosis,  microangio-
pathic  hemolytic  anemia,  thrombocytopenia
and organ failure. The most common of these
disorder,  hemolytic  uremic  syndrome  (HUS)
and TTP, were once considered 2 distinct dis-
ease etiologies. In consideration of their exten-
sive  pathophysiologic  overlap,  they  are  now
termed  the  HUS/TTP  syndrome.  The  classic
clinical pentad of TTP includes i) fever, ii) neu-
rologic  symptoms,  iii)  microangiopathic
hemolytic anemia, iv) thrombocytopenic purpu-
ra, and v) the presence of thrombi in glomeru-
lar capillaries and afferent arterioles. Although
hemolytic anemia is a universal feature, all 5
classic  findings  are  present  in  only  40%  of
cases. Thrombotic thrombocytopenic purpura is
seen more often in women, with most of the
patients younger than 40 years, the diagnosis
rests on evidence of microangiopathic hemolyt-
ic anemia and thrombocytopenia in the absence
of  DIC  or  other  known  causes  of  thrombotic
microangiopathy.  There are no clinical features
or laboratory tests that can confirm the diagno-
sis of TTP-HUS; the most important diagnostic
criterion,  but  also  the  most  difficult,  is  the
exclusion  of  alternative  etiologies.9,10
ADAMTS13 (A Disintegrin And Metallo-protease
with  ThromboSpondin-1-like  domains),  an
enzyme required for normal proteolytic process-
ing of von Willebrand factor (VWF), is important
in the pathophysiology of TTP, but patients may
have  characteristic  presenting  features  and
clinical courses without severe ADAMTS13 defi-
ciency.11,12 Even after a diagnosis of thrombotic
thrombocytopenic purpura is made, continuing
evaluation  is  important.  In  the  Oklahoma
Thrombotic  Thrombocytopenic  Purpura-
Hemolytic  Uremic  Syndrome  (TTP-HUS)
Registry, 10 percent of patients with an initial
diagnosis of idiopathic thrombotic thrombocy-
topenic  purpura  were  subsequently  found  to
have sepsis or systemic cancer (Table 1).
Case Report
A  34-yer-old  man  without  significant  past
medical  history  was  found  lethargic  in  bed
early morning and sudden onset of respiratory
failure. The patient was on no medications and
had no drug allergies. He did not smoke or use
drugs. There was no family history of major
medical problems. The patient was transferred
to the emergency department (ED) by ambu-
lance. Upon arrival at the ED his conscious-
ness  level  was  rated  on  the  Glasgow  Coma
Scale  as  6/15,  (E2V1M3),  he  was  somnolent
and unable to follow commands. His mental
status worsened, and the trachea was intubat-
ed  for  airway  protection  with  use  of  rapid-
sequence  induction.  Physical  examination
revealed an obese white male in acute distress.
His  vital  signs  were:  temperature,  38,5°C;
pulse,  125  beats/min;  respirations,  24
breaths/min; and blood pressure 90/50 mmHg.
Head examination found no signs of trauma.
Pupils were equal and reactive to light. The
neck examination revealed jugular and supra-
clavicular lymphadenopathies with a firm and
rubbery  consistency.  The  abdomen  was  soft
and  tender  with  a  3  cm  hepatomegaly.
Tachypnea and use of accessory muscles were
present. Cardiac examination revealed tachy-
cardia but regular rhythm without murmurs,
rubs, or gallops. The skin was mottled, without
petechiae; the extremities were cool and clam-
my, with acral cyanosis. The patient was sedat-
ed and mechanically ventilated with an inspi-
ratory  oxygen  concentration  of  60  percent.
Results of laboratory tests on admission were
as  follows;  leukocyte,  6400/mL;  hematocrit,
23.6%, hemoglobin, 7.7 g/dL; peripheral smear
showed moderate-to-severe schistocytosis and
marked  red  cell  fragmentation  ;  platelet
60,000/mL, serum glucose 123 mg/dL, serum
urea 86 mg/dL, serum creatinine 2.86 mg/dL ,
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serum sodium 139 mg/dL, serum potassium 6.2
mg/dL,  total  bilirubin  6.8  mg/dL,  aspartate
aminotransferase,  5318  U/L,  alanine  amino-
transferase  1947  U/L,  lactate  dehydrogenase
19,758 U/L. Blood coagulation tests; prothrom-
bin time, 23,1 sec, activated partial thrombo-
plastin time 53.2 sec. ; Fibrinogen 3.9 g/L (2.0-
6.0)  all  within  normal  values;  D-dimer  5250
ng/dL.  A  Coomb’s  tests  showed  a  negative
result.  Toxicologic  screening  of  serum  was
negative for ethanol, acetaminophen, and sali-
cylates, and toxicologic screening of urine was
also negative. Blood cultures failed to grow any
organism. Antibody titer for human immunod-
eficiency virus was normal. A chest radiograph
was  normal,  and  a  bedside  echocardiogram
showed  no  pericardial  fluid.  Specimens  of
blood and urine were taken for bacterial and
viral  cultures  and  testing  for  viral  antigens.
Toraco-abdominal computed tomography (CT)
revealed enlarged esophageal and paracardiac
lymph nodes, bilateral posterobasal lung con-
solidations,  hepatosplenomegaly,  multiple
enlarged retroperitoneal and paraaortic lymph
nodes (Figure 1).
A  definite  diagnosis  could  not  be  deter-
mined on admission because of the complexi-
ty of signs and symptoms, the diagnosis of TTP
was suggested based on the presence of fever,
neurologic  symptoms,  microangiopathic
hemolytic  anemia,  thrombocytopenia,  renal
failure, increased serum levels of lactate dehy-
drogenase and indirect-reacting bilirubin, and
negative direct Coomb’s test. Plasma exchange
therapy and supportive care was begun. It was
critical to rule out disseminated cancer. The
importance  of  prompt  diagnosis  of  the  sys-
temic malignancy was to provide an opportuni-
ty for treatment with appropriate chemothera-
py.  In the Intensive Care Unit treatment with
dopamine to maintain a systolic blood pressure
of 140 was started, and aggressive fluid resus-
citation  was  continued.  Two  hours  later  the
blood  pressure  decreased  to  90/45  mm  Hg;
Norepinephrine  was  added.  After  obtaining
informed consent from his family bone marrow
aspiration sample was obtained. Twenty-nine
hours after presentation the axillary tempera-
ture was 40.4°C (104.8°F) and the blood pres-
sure 82/55 mm Hg despite increasing doses of
dopamine,  epinephrine,  and  norepinephrine.
Laboratory  evaluation  demonstrated  severe
anemia (hematocrit 23%) despite blood trans-
fusion,  thrombocytopenia  (platelet  count
20,000/mL),  coagulation  tests  (international-
ized normalized ratio (INR), 1.2; activated par-
tial prothrombin time, 25 s; fibrinogen concen-
tration, 3.3 g/L (2.0-6.0) were normal. Results
of  Microbiologic  and  Serologic  Tests  were
received, Blood culture negative, Urine culture
negative, Cytomegalovirus antigenemia assay
negative, Epstein-Barr virus anti-VCA IgG pos-
tive, Epstein-Barr virus anti-VCA IgM negative,
Epstein-Barr  virus  early  antigen  negative,
Epstein–Barr virus antinuclear antigen nega-
tive, Herpes simplex virus type 1 antibody IgG
positive, Herpes simplex virus type 2 antibody
IgG  negative,  Carcinoembryonic  antigen
(ng/mL) 1.4, Prostate-specific antigen (ng/mL)
4.6, CA-125 (U/mL) 36, CA 19-9 (U/mL) 6.1,
Rheumatoid factor (IU/mL) <30, Antinuclear
antibody negative, Antineutrophil cytoplasmic
antibody Negative, Hepatitis B surface antigen
Negative,  Hepatitis  C  antibody  negative,
ADAMTS13  (<  20%)  Thirty-one  hours  after
presentation, bradycardia developed, followed
rapidly  by  asystole,  and  cardiopulmonary
resuscitation  was  initiated.  The  patient  was
pronounced dead 32 hours after arrival in the
emergency room. The marrow aspirate results
were received with occupation by neoplastic
cells of large size and frequent syncytia. The
autopsy revealed a tumor at the ileum 10 cm
proximal from the ileocecal region. Peritoneal
dissemination was recognized around the ileo-
cecal  region,  pathological  diagnosis  of  the
specimen  was  adenocarcinoma  with  lymph
nodes metastasis.
Discussion
Microangiopathic  hemolytic  anemia  and
thrombocytopenia caused by systemic malig-
nancies  have  been  well  described,  but  it  is
uncommon  for  microangiopathic  hemolytic
anemia and thrombocytopenia to be the pre-
dominant  presenting  clinical  features  in
patients whose systemic malignancy is not ini-
Case Report
Figure 1. Abdominal CT scan demonstrates A) pathological hepatic lymph nodes and B)
retroperitoneal lymph nodes.
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Table 1. Clinical features that may suggest disseminated malignancy as an alternative
diagnosis in patients with assumed TTP-HUS.
Clinical feature Comment
History of cancer Even when the clinical evaluation and results 
of imaging studies are normal metastatic cancer must 
be suspected
Pulmonary infiltrates Rare in TTP-HUS
Respiratory failure Acute respiratory symptoms are rare in TTP-HUS. 
Disseminated intravascular coagulation (DIC) Although DIC is commonly associated with metastatic 
carcinoma, coagulation tests may be normal.
Nucleated red blood cells and immature  These abnormalities may accompany the marrow 
myeloid cells on peripheral blood smear response to severe hemolysis, but they commonly 
indicate marrow infiltration by tumor.
Extreme elevation of lactate  Although an elevated LDH level, caused by hemolysis 
dehydrogenase (LDH) level and tissue ischemia, is characteristic of TTP-HUS, 
levels exceeding 5,000 U/L are more commonly cause 
by tumor lysis
No response to plasma exchange therapy Patients with TTP-HUS typically respond promptly to 
plasma exchange. No response should cause concern 
about the diagnosis.
Extreme elevations of D-dimer D-dimers were found severely increased in all cases of
disseminated cancer presenting as TTP
ADAMTS13 activity ADAMTS13 activity may be normal or lower than normal
in cancer-associated TTP. [Hematology Reports 2011; 3:e14]
tially  apparent.  Although  occult  malignancy
causing  microangiopathic  hemolytic  anemia
and thrombocytopenia may be uncommon, it is
an important consideration in the evaluation
of patients for TTP. In the Oklahoma TTP-HUS
Registry, 10 (3%) of 351 patients who were ini-
tially  diagnosed  as  having  TTP  and  treated
with plasma exchange were subsequently and
unexpectedly  diagnosed  with  disseminated
malignancy.  Only  systemic  infections  have
been a more common cause of an incorrect ini-
tial diagnosis of TTP in the Oklahoma Registry.
Many different malignancies may mimic TTP;
the importance of prompt diagnosis of the sys-
temic malignancy is to provide an opportunity
for treatment with appropriate chemotherapy.
Early  recognition  of  cancer  may  not  benefit
many patients who present with microangio-
pathic hemolytic anemia and thrombocytope-
nia since these patients often have widely dis-
seminated cancer. Even though treatment suc-
cess  may  be  limited,  prompt  diagnosis  is
important  for  appropriate  management.
Prompt  diagnosis  of  systemic  malignancy  is
also important in avoiding unnecessary risks
of plasma exchange treatment for TTP. The dif-
ficulty  of  diagnosing  a  systemic  malignancy
presenting  with  microangiopathic  hemolytic
anemia and thrombocytopenia is evidence in
literature.13 The  diagnosis  of  disseminated
malignancy excludes the diagnosis of TTP or
HUS; these patients should not be considered
to have cancer-associated TTP. Although multi-
ple etiologies may contribute to the syndromes
recognized  as  TTP  and  HUS,  disseminated
malignancy  is  a  pathologically  and  clinically
distinct  disorder.  Disseminated  malignancy
can cause microangiopathic hemolytic anemia
and thrombocytopenia, in the absence of DIC,
by microvascular tumor emboli. This has been
most frequently observed with diffuse micro-
scopic pulmonary involvement.14,15 ADAMTS13
activity is not severely deficient but may be
lower than normal in some patients with dis-
seminated malignancy due to high plasma lev-
els  of  von  Willebrand  factor.16,17 Plasma
exchange has no role in management when a
malignant disorder is recognized. Clues that
may  suggest  the  presence  of  an  occult  sys-
temic  malignancy  include  presenting  symp-
toms of dyspnea, cough, and pain other than
abdominal  pain.  Although  increased  serum
LDH  is  characteristic  of  patients  with  TTP,
extreme  elevations  are  not  typical  and  may
suggest tumor lysis. Median LDH level was 4.5
times  upper  the  normal  values  (range,  3.2-
8.9). D-dimers were found severely increased
in all cases of disseminated cancer presenting
as TTP in a recent report of several cases of
disseminated cancer.18 Perhaps the most con-
vincing clue that a patient with presumed TTP
may have a disseminated malignancy is failure
to respond to plasma exchange. If systematic
malignancy is suspected, bone marrow biopsy
is appropriate.19,20
Conclusions
The evaluation and management of patients
who present with an acute onset of microan-
giopathic  hemolytic  anemia  and  thrombocy-
topenia  remain  critical  challenges  for  clini-
cians.  Although  the  diagnosis  of  TTP  and
urgent treatment with plasma exchange must
be  considered  in  patients  with  microangio-
pathic hemolytic anemia and thrombocytope-
nia, the possibility that all of the clinical fea-
tures of TTP may be caused by an occult dis-
seminated  malignancy  must  be  appreciated.
With increased awareness of the possible diag-
nosis of disseminated malignancy, the diagno-
sis can be made sooner, avoiding unnecessary
plasma  exchange  treatment  and  allowing
appropriate chemotherapy treatment
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